Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Osiris begins phase II study of Prochymal for type 1 diabetes

Oct. 29, 2007

New ghrelin receptor antagonists with potential for the treatment of diabetes and obesity

Oct. 29, 2007

Vitor will undergo pilot phase III trial in order to finalize special protocol assessment

Oct. 29, 2007

NPS Pharmaceuticals receives Japanese approval for cinacalcet hydrochloride

Oct. 29, 2007

Mutations in PEX2 identified as the cause of Zellweger syndrome

Oct. 26, 2007

Raptor establishes subsidiary and acquires first clinical-stage product

Oct. 26, 2007

Genzyme's Cholestagel launched in Europe

Oct. 25, 2007

Genzyme's Elaprase IV 6 mg launched in Japan

Oct. 25, 2007

Orexigen's Contrave begins third phase III trial for treatment of obesity

Oct. 25, 2007

Positive results reported for phase I FT-105 basal insulin trial

Oct. 25, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...